<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67325">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02151539</url>
  </required_header>
  <id_info>
    <org_study_id>VICC BMT 1401</org_study_id>
    <secondary_id>NCI-2014-01026</secondary_id>
    <secondary_id>VICC BMT 1401</secondary_id>
    <secondary_id>P30CA068485</secondary_id>
    <nct_id>NCT02151539</nct_id>
  </id_info>
  <brief_title>Medical Chart Review in Determining Outcomes of Second-Line Therapy in Patients With Acute Graft-versus-host Disease Previously Treated With Extracorporeal Photopheresis or Other Systemic Therapies</brief_title>
  <acronym>POSTAGE</acronym>
  <official_title>Prospective Outcomes of Second-Line Therapy in Acute Graft-Versus-Host Study Including ECP (POSTAGE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research trial studies medical chart review in determining outcomes of second-line
      therapy in patients with acute graft-versus-host disease previously treated with
      extracorporeal photopheresis or other systemic therapies. Gathering information about
      second-line therapy in patients with acute graft-versus-host disease may help doctors learn
      more about the disease and find better treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine 6-month freedom from treatment failure for second-line therapy for acute
      graft versus host disease (aGVHD).

      II. To show that extracorporeal photopheresis (ECP) is associated with a superior 6 month
      (m) freedom from treatment failure (FFTF) as compared to other treatment modalities for
      second line therapy for aGVHD.

      III. To describe health care burden in patients receiving second line therapy for acute
      GVHD.

      IV. Quality of life measurement using Functional Assessment of Cancer Therapy-Bone Marrow
      Transplant (FACT-BMT) in patients receiving second line therapy for aGVHD.

      OUTLINE:

      Study data are collected and managed using Research Electronic Data Capture (REDCap) tools
      at baseline and on days 5, 28, and 56.

      After completion of study, patients are followed up at 6 months, and 1 and 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>6-month freedom from treatment failure, defined as a patient being alive, without relapse of underlying disease, and without the addition of new systemic therapy for the treatment of aGVHD, within 6 months of starting second line therapy</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rates of 6 m FFTF will be estimated by subtracting rates of total failures from 100%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative incidence estimates of relapse</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cox regression models will be used to identify risk factors for failure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative incidence estimates of non-relapse mortality</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cox regression models will be used to identify risk factors for failure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment change as causes of failure during second line treatment</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cox regression models will be used to identify risk factors for failure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health care burden in patients receiving second line therapy for acute GVHD</measure>
    <time_frame>Up to 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The incremental budget spend between the patients receiving treatment with ECP and patients receiving other modalities will be measured and economic methods will be used to calculate an incremental cost effectiveness ratio for relevant clinical end points. Health economic data relating to hospitalizations (length of stay in myelosuppressive unit, high-dependency unit [step-down unit], intensive care unit), high cost drugs, total parenteral nutrition and surgical procedures will also be collected allowing comparisons to be made between patients treated with ECP and other treatment options.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life measured using FACT-BMT</measure>
    <time_frame>Up to 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Graft Versus Host Disease</condition>
  <arm_group>
    <arm_group_label>Observational (medical chart review)</arm_group_label>
    <description>Study data are collected and managed using REDCap tools at baseline and on days 5, 28, and 56.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>medical chart review</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Observational (medical chart review)</arm_group_label>
    <other_name>chart review</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Observational (medical chart review)</arm_group_label>
    <other_name>quality of life assessment</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study targets patients with acute graft-versus-host disease previously treated with
        extracorporeal photopheresis or other systemic therapies. Patients can be enrolled by all
        participating locations.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Enrollment on study is within 5 days (including weekends) of starting second-line
             therapy

          -  aGVHD grade 2 or higher at time of enrollment; patients with late acute and recurrent
             aGVHD are permitted

          -  Donor lymphocyte induced aGVHD is permitted ONLY IF donor lymphocyte infusion given
             for mixed chimerism and not for progression of disease and meeting all other
             inclusion and exclusion criteria will be eligible

          -  Corticosteroid refractory or corticosteroid dependent aGVHD

               -  Corticosteroid refractory aGVHD is defined as worsening of aGVHD after 3 days of
                  systemic corticosteroids (minimum dose of 1 mg/kg), or no improvement after 7
                  days of systemic corticosteroids (minimum dose of 1 mg/kg)

               -  Corticosteroid dependent aGVHD is defined as recurrence of aGVHD (grade 2 or
                  higher) during corticosteroid taper and prior to reaching 50% of initial
                  starting dose of corticosteroids

          -  Informed consent form

        Exclusion Criteria:

          -  Has received corticosteroids at 2 mg/kg or higher for 3 weeks or longer as part of
             first-line therapy for aGVHD

          -  Has received systemic therapy other than corticosteroids for treatment of aGVHD as
             part of first-line therapy for acute GVHD; simultaneous uses of topical or enteric
             corticosteroids or psoralen plus ultraviolet A (PUVA) for first-line are permitted

          -  aGVHD after second hematopoietic cell transplantation (HCT) is excluded

          -  Karnofsky performance status =&lt; 50%

          -  Requiring mechanical ventilation or renal replacement therapy at the time of
             enrollment

          -  Histologic or flow-cytometric evidence of relapse or progression of underlying
             disease; molecular or cytogenetic presence of disease is permitted; mixed chimerism
             is permitted

          -  Current or prior diagnosis of chronic GVHD (classic or overlap) as defined by
             National Institutes of Health (NIH) consensus criteria

          -  Donor lymphocyte infusion (DLI)-induced aGVHD when DLI was given for progression of
             the underlying disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Madan Jagasia</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vanderbilt Cancer Center Clinical Trial Information Program</last_name>
    <phone>800-811-8480</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nandita Khera</last_name>
      <phone>480-342-3047</phone>
      <email>khera.nandita@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Nandita Khera</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Hospital - Westwood Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sunil H. Abhyankar</last_name>
      <phone>913-588-6029</phone>
      <email>sabhyankar@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Sunil H. Abhyankar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shahrukh K. Hashmi</last_name>
      <phone>507-538-3270</phone>
      <email>Hashmi.Shahrukh@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Shahrukh K. Hashmi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Madan H. Jagasia</last_name>
      <phone>615-936-8422</phone>
      <email>madan.jagasia@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Madan H. Jagasia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hildegard Greinix</last_name>
      <phone>43 1 40400 4457</phone>
      <email>Hildegard.greinix@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Hildegard Greinix</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universit√§t Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Wolff</last_name>
      <phone>0941-944-5531</phone>
      <email>daniel.wolff@ukr.de</email>
    </contact>
    <investigator>
      <last_name>Daniel Wolff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emma Das-Gupta</last_name>
      <phone>01159691169 Ext 54666</phone>
      <email>emma.das-gupta@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Emma Das-Gupta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Austria</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>May 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Madan Jagasia, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
